SEC Form SC 13G/A filed by ACADIA Pharmaceuticals Inc. (Amendment)

2/9/24 8:35:54 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $ACAD alert in real time by email

SC 13G/A 1 filing.txt SCHEDULE 13G Amendment No.18 ACADIA PHARMACEUTICALS INC COMMON STOCK Cusip #004225108 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #004225108 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 5,263,805 Item 6: 0 Item 7: 5,265,357 Item 8: 0 Item 9: 5,265,357 Item 11: 3.207% Item 12: HC Cusip #004225108 Item 1: Reporting Person - Abigail P. Johnson Item 2: (a) [ ] (b) [ ] Item 4: United States of America Item 5: 0 Item 6: 0 Item 7: 5,265,357 Item 8: 0 Item 9: 5,265,357 Item 11: 3.207% Item 12: IN Item 1(a). Name of Issuer: ACADIA PHARMACEUTICALS INC Item 1(b). Address of Issuer's Principal Executive Offices: 3611 Valley Centre Drive, Suite 300 San Diego, CA 92130 USA Item 2(a). Name of Person Filing: FMR LLC Item 2(b). Address or Principal Business Office or, if None, Residence: 245 Summer Street, Boston, Massachusetts 02210 Item 2(c). Citizenship: Not applicable Item 2(d). Title of Class of Securities: COMMON STOCK Item 2(e). CUSIP Number: 004225108 Item 3. This statement is filed pursuant to Rule 13d-1(b) or 13d-2(b) or (c) and the person filing, FMR LLC, is a parent holding company in accordance with Section 240.13d-1(b)(1)(ii)(G). (Note: See Exhibit A). Item 4. Ownership (a) Amount Beneficially Owned: 5,265,357 (b) Percent of Class: 3.207% (c) Number of shares as to which such person has: (i) sole power to vote or to direct the vote: Please see the responses to Items 5 and 6 on the cover page (ii) shared power to vote or to direct the vote: 0 (iii) sole power to dispose or to direct the disposition of: 5,265,357 (iv) shared power to dispose or to direct the disposition of: 0 Item 5. Ownership of Five Percent or Less of a Class. If this statement is being filed to report the fact that as of the date hereof, the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following (X). Item 6. Ownership of More than Five Percent on Behalf of Another Person. One or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the COMMON STOCK of ACADIA PHARMACEUTICALS INC. No one other person's interest in the COMMON STOCK of ACADIA PHARMACEUTICALS INC is more than five percent of the total outstanding COMMON STOCK. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. See attached Exhibit A. Item 8. Identification and Classification of Members of the Group. Not applicable. Item 9. Notice of Dissolution of Group. Not applicable. Item 10. Certifications. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. Signature After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. February 8, 2024 Date /s/ Stephanie J. Brown Signature Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries* * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. Exhibit A Pursuant to the instructions in Item 7 of Schedule 13G, the following table lists the identity and Item 3 classification, if applicable, of each relevant entity that beneficially owns shares of the security class being reported on this Schedule 13G. Entity ITEM 3 Classification Fidelity Management & Research Company LLC IA Fidelity Management Trust Company BK Strategic Advisers LLC IA Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. This filing reflects the securities beneficially owned, or that may be deemed to be beneficially owned, by FMR LLC, certain of its subsidiaries and affiliates, and other companies (collectively, the "FMR Reporters"). This filing does not reflect securities, if any, beneficially owned by certain other companies whose beneficial ownership of securities is disaggregated from that of the FMR Reporters in accordance with Securities and Exchange Commission Release No. 34-39538 (January 12, 1998). RULE 13d-1(k)(1) AGREEMENT The undersigned persons, on February 8, 2024, agree and consent to the joint filing on their behalf of this Schedule 13G in connection with their beneficial ownership of the COMMON STOCK of ACADIA PHARMACEUTICALS INC at December 29, 2023. FMR LLC By /s/ Stephanie J. Brown Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries* Abigail P. Johnson By /s/ Stephanie J. Brown Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 26, 2023, by and on behalf of Abigail P. Johnson** * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. ** This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 31, 2023, accession number: 0000315066-23-000038.

Get the next $ACAD alert in real time by email

Recent Analyst Ratings for

$ACAD

Date	Price Target	Rating	Analyst
10/10/2024		Mkt Perform	Raymond James
8/7/2024	$28.00 → $20.00	Overweight → Equal-Weight	Morgan Stanley
6/27/2024	$31.00	Outperform	BMO Capital Markets
3/12/2024	$36.00 → $32.00	Buy	Needham
3/12/2024	$39.00 → $25.00	Buy → Neutral	Mizuho
1/30/2024	$40.00	Outperform	Robert W. Baird
1/24/2024	$37.00	Hold → Buy	Needham
12/19/2023	$31.00 → $40.00	Equal-Weight → Overweight	Morgan Stanley

More analyst ratings

SEC Form SC 13G/A filed by ACADIA Pharmaceuticals Inc. (Amendment)

Chat with this insight

Recent Analyst Ratings for $ACAD

$ACAD Leadership Updates

Live Leadership Updates

Catherine Owen Adams Succeeds Steve Davis as CEO of Acadia Pharmaceuticals

Acadia Appoints Elizabeth H. Z. Thompson, Ph.D. as Executive Vice President, Head of Research and Development

Acadia Pharmaceuticals Appoints Albert Kildani as Senior Vice President, Investor Relations and Corporate Communications

$ACAD Financials

Live finance-specific insights

Acadia Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operating Overview

Acadia Pharmaceuticals to Announce Third Quarter Financial Results on November 6, 2024

Acadia Pharmaceuticals Reports Second Quarter 2024 Financial Results and Operating Overview

$ACAD Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Raymond James resumed coverage on ACADIA Pharmaceuticals

ACADIA Pharmaceuticals downgraded by Morgan Stanley with a new price target

BMO Capital Markets initiated coverage on ACADIA Pharmaceuticals with a new price target

$ACAD SEC Filings

SEC Form 8-K filed by ACADIA Pharmaceuticals Inc.

ACADIA Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

SEC Form S-8 filed by ACADIA Pharmaceuticals Inc.

$ACAD Press Releases

Fastest customizable press release news feed in the world

Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Acadia Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operating Overview

$ACAD Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

EVP, COO, HEAD OF COMMERCIAL Teehan Brendan converted options into 19,826 shares and sold $173,630 worth of shares (10,329 units at $16.81), increasing direct ownership by 18% to 62,105 units (SEC Form 4)

PRINCIPAL ACCOUNTING OFFICER Kihara James converted options into 7,930 shares and sold $68,467 worth of shares (4,073 units at $16.81), increasing direct ownership by 24% to 19,863 units (SEC Form 4)

EVP, CHIEF FINANCIAL OFFICER Schneyer Mark C. converted options into 19,826 shares and sold $172,454 worth of shares (10,259 units at $16.81), increasing direct ownership by 22% to 53,302 units (SEC Form 4)

$ACAD FDA approvals

Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

FDA Approval for NUPLAZID issued to ACADIA PHARMS INC

FDA Approval for NUPLAZID issued to ACADIA PHARMS INC

FDA Approval for DAYBUE issued to ACADIA PHARMS INC

$ACAD Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by ACADIA Pharmaceuticals Inc.

SEC Form SC 13G filed by ACADIA Pharmaceuticals Inc.

SEC Form SC 13G/A filed by ACADIA Pharmaceuticals Inc. (Amendment)

$ACAD Market Insights

Live Market Insights

A Closer Look at 13 Analyst Recommendations For ACADIA Pharmaceuticals

Morgan Stanley Maintains Overweight on ACADIA Pharmaceuticals, Lowers Price Target to $28

Recent Analyst Ratings for
$ACAD

$ACAD
Leadership Updates

$ACAD
Financials

$ACAD
Analyst Ratings

$ACAD
SEC Filings

$ACAD
Press Releases

$ACAD
Insider Trading

$ACAD
FDA approvals

$ACAD
Large Ownership Changes

$ACAD
Market Insights